PTGXProtagonist Therapeutics, Inc.
Price
+131%1YEnd-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, nothing alarming, demanding price, growing in the filings, the market undecided.
Protagonist Therapeutics, Inc. (referred to as “Protagonist,” the “Company,” “we,” “our” or “us”) is an integrated discovery and development company with a validated technology platform. Our programs fall into three broad therapeutic areas: (i) inflammation and immunology (“I&I”), (ii) hematology and (iii) metabolic diseases. Our aim is to develop medicines for biologically and commercially validated targets which demonstrate a strong differentiation compared to existing therapies.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Protagonist Therapeutics, Inc. (PTGX) reported revenue of $213M in Q2 2026 (quarter ended Jun 30, 2026), up 3749% from the same quarter a year earlier. That came with net income of $163M (76% of revenue). For the full year FY2025, revenue was $46M (−89% year on year) and net income −$130M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Jun 18, 2026At the Annual Meeting, the Company’s stockholders approved the adoption of the Company’s 2026 Equity Incentive Plan (the “2026 Plan”)Director or officer change · Form 8-K
- May 5, 2026Protagonist Reports First Quarter 2026 Financial.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.